MEMS-based Pulmonary Artery (PA) Sensor Implant, Which Empowers Proactive Heart Failure Management in the Home
Heart failure (HF) is a debilitating, progressive disease impacting the everyday life of over 6M patients in the US alone. Despite advances in medications and other interventions patient still suffer from increased mortality and repeat hospitalizations. Given the huge burden of managing these patients, health care providers need new solutions.
The FDA-approved Cordella® HF System is a next generation solution that empowers proactive heart failure management in the home. By enabling daily collection of intracardiac Pulmonary Artery Pressure (PAP) pressure using an implantable MEMS sensor as well as patient vitals, the system provides caregivers a comprehensive view of the disease progression that facilitates proactive medication changes keeping patients heathy and out of the hospital. For the first time Cordella® HF System allows patients to see their PAP trends so they can better understand their condition and how their lifestyle choices affect their health, leading to high levels of engagement and better outcomes.
This presentation will describe the clinical need being addressed by the Cordella® HF System, key components of the system including its unique attributes and how the system is used by the patients and clinicians to improve care and clinical outcomes.
BIOGRAPHY
Angad Singh has almost 25 years of technology development and product leadership experience in the commercialization of ground-breaking medical products with a strong focus in implantable wireless MEMS sensors for medical applications. As Chief Technology Officer and Head of R&D at Endotronix (now part of Edwards Lifesciences), he leads product development and innovation for the Cordella® HF System, a next generation digital health platform for managing heart failure patients that combines an implantable wireless sensor measuring intracardiac pressures with vital signs and patient reported symptoms to guide proactive and precise therapeutic interventions. He previously served as Vice President of Engineering and Operations at CardioMEMS (now part of Abbott Laboratories), the first company to commercialize implantable wireless sensors for disease monitoring, where his technical expertise and leadership were crucial in the transition of their Aortic Abdominal Aneurysm (AAA) and Heart Failure (HF) monitoring products from concept to commercialization and revenues in excess of $100M. More recently, Mr. Singh co-founded Polaris Surgical (now part of MiRus), where he led the development and commercialization of next generation surgical guidance systems and smart instrumentation to improve orthopedic and spine surgeries including the award-winning GALILEO™ Spinal Alignment Monitoring System, a first-of-a-kind real-time measurement and monitoring system. Prior positions include co-founder and Chief Technology Officer at Microgen Systems, Staff Engineer at SONY, and R&D Engineer at the Berkeley Sensor and Actuator Center. Mr. Singh has an M.S. degree in Electrical Engineering and Applied Physics from Case Western Reserve University and a B.S. degree in Electrical Engineering from the Visvesvaraya National Institute of Technology, India.